Luca Gianni Selected Research

4'-deoxydoxorubicinol

2/2007

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luca Gianni Research Topics

Disease

70	Breast Neoplasms (Breast Cancer) 10/2022 - 01/2002
38	Neoplasms (Cancer) 10/2022 - 07/2002
11	Cardiotoxicity 02/2009 - 01/2002
8	Pathologic Complete Response 06/2022 - 10/2005
8	Neutropenia 01/2021 - 03/2005
7	Triple Negative Breast Neoplasms 06/2022 - 01/2011
6	Disease Progression 01/2021 - 10/2004
5	Adenocarcinoma 01/2020 - 07/2016
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2019 - 06/2003
5	Fatigue 10/2018 - 08/2009
4	Brain Neoplasms (Brain Tumor) 06/2022 - 01/2016
4	Febrile Neutropenia 01/2021 - 05/2013
4	Thrombocytopenia (Thrombopenia) 01/2017 - 01/2006
4	Inflammatory Breast Neoplasms 06/2016 - 01/2010
4	Heart Failure 01/2010 - 06/2004
3	Carcinoma (Carcinomatosis) 10/2020 - 03/2005
2	Diarrhea 01/2021 - 11/2012
2	Carcinogenesis 10/2020 - 01/2002
2	Lung Neoplasms (Lung Cancer) 12/2018 - 01/2018
2	Stomatitis 01/2018 - 05/2014
2	Neoplasm Metastasis (Metastasis) 01/2016 - 12/2010
2	Vomiting 10/2013 - 11/2012
2	Nausea 10/2013 - 11/2012
2	Cardiomyopathies (Cardiomyopathy) 01/2007 - 06/2004
2	Ovarian Neoplasms (Ovarian Cancer) 03/2005 - 06/2003
1	Anemia 01/2021
1	Leukopenia 01/2021
1	Myasthenia Gravis 03/2019
1	Polyneuropathies (Polyneuropathy) 03/2019

Drug/Important Bio-Agent (IBA)

39	Trastuzumab (Herceptin)FDA Link 10/2022 - 01/2002
15	AnthracyclinesIBA 10/2022 - 01/2002
13	pertuzumabIBA 10/2022 - 03/2010
13	human ERBB2 proteinIBA 10/2022 - 03/2010
13	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2014 - 01/2003
12	Paclitaxel (Taxol)FDA LinkGeneric 03/2018 - 01/2003
11	ErbB Receptors (EGF Receptor)IBA 10/2022 - 07/2002
9	Pharmaceutical PreparationsIBA 01/2022 - 03/2005
9	Docetaxel (Taxotere)FDA Link 01/2017 - 07/2006
8	taxaneIBA 10/2022 - 03/2005
8	Capecitabine (Xeloda)FDA Link 01/2021 - 10/2006
7	Estrogen ReceptorsIBA 01/2022 - 12/2005
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2014 - 05/2004
7	Fluorouracil (Carac)FDA LinkGeneric 01/2014 - 05/2004
7	Methotrexate (Mexate)FDA LinkGeneric 01/2014 - 05/2004
6	Ado-Trastuzumab EmtansineIBA 10/2022 - 11/2012
6	Biomarkers (Surrogate Marker)IBA 07/2022 - 02/2008
5	Taxoids (Taxanes)IBA 10/2022 - 10/2004
5	Hormones (Hormone)IBA 10/2022 - 12/2010
5	ParaffinIBA 02/2019 - 10/2005
5	Cisplatin (Platino)FDA LinkGeneric 10/2018 - 10/2013
5	Monoclonal AntibodiesIBA 01/2017 - 01/2002
4	Estrogens (Estrogen)FDA Link 01/2022 - 01/2013
4	Gemcitabine FDA Link 01/2021 - 07/2016
4	Formaldehyde (Formol)FDA Link 02/2019 - 01/2014
4	130-nm albumin-bound paclitaxelIBA 10/2018 - 07/2016
4	Epirubicin (Ellence)FDA LinkGeneric 06/2012 - 06/2004
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 10/2020
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2014
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 01/2011
3	LigandsIBA 01/2021 - 04/2007
3	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 04/2015
3	Lapatinib (GW572016)FDA Link 01/2017 - 11/2011
3	Transaminases (Aminotransferases)IBA 10/2013 - 03/2005
3	Tyrosine Kinase InhibitorsIBA 02/2004 - 01/2002
2	sacituzumab govitecanIBA 06/2022 - 01/2021
2	palbociclibIBA 01/2022 - 01/2018
2	Immune Checkpoint InhibitorsIBA 03/2019 - 01/2018
2	IntegrinsIBA 02/2019 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 02/2019 - 01/2019
2	Phenobarbital (Luminal)FDA Link 03/2018 - 12/2010
2	AntibodiesIBA 01/2017 - 04/2007
2	Progesterone Receptors (Progesterone Receptor)IBA 06/2016 - 01/2011
2	Bevacizumab (Avastin)FDA Link 01/2016 - 05/2013
2	Cytotoxins (Cytolysins)IBA 04/2015 - 10/2004
2	Everolimus FDA Link 05/2014 - 01/2011
2	TrabectedinIBA 10/2013 - 03/2005
2	ProdrugsIBA 10/2010 - 10/2006
2	Free RadicalsIBA 01/2008 - 06/2004
2	quinone (benzoquinone)IBA 01/2008 - 04/2006
2	IronIBA 01/2008 - 06/2004
2	adriamycinolIBA 02/2007 - 07/2006
2	Gefitinib (Iressa)FDA Link 02/2004 - 06/2003
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	Cyclin D1IBA 01/2022
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	eribulin FDA Link 01/2021
1	Neuregulin-1 (Neuregulin 1)IBA 01/2021
1	Topoisomerase I InhibitorsIBA 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Conditioned Culture MediaIBA 01/2021
1	pembrolizumabIBA 03/2019
1	NivolumabIBA 03/2019

Therapy/Procedure

40	Therapeutics 07/2022 - 06/2003
33	Drug Therapy (Chemotherapy) 01/2022 - 11/2004
14	Neoadjuvant Therapy 06/2022 - 01/2010
5	Adjuvant Chemotherapy 06/2022 - 10/2005
3	Immunotherapy 03/2019 - 01/2018
2	Salvage Therapy 01/2022 - 03/2005
2	Radiotherapy 01/2018 - 07/2014
1	Duration of Therapy 01/2020